| User's Publication |
|
21627
Shimizu D, Ishibashi M, Yamada T, Toda Y, Hosogi S, Ashihara E.
POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.
Cancer Genomics Proteomics
2024
21(2):158-165
PubMed ID: 38423601
DOI: 10.21873/cgp.20437
|
|
21908
Ito M, Koido S, Iwamoto T, Morimoto S, Fujiki F, Sugiyama H, Matsumoto S, Effenberger C, Kiyotani K, Shiba K.
Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors.
PLoS One
2024
19(8):e0308330
PubMed ID: 39116074
DOI: 10.1371/journal.pone.0308330
|
|
19895
Mori K, Matsumoto K, Ikeda M, Koguchi D, Shimizu Y, Tsumura H, Ishii D, Tsuji S, Sato Y, Iwamura M.
Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer
Diagnostics (Basel)
2023
13(19):3067
PubMed ID: 37835810
DOI: 10.3390/diagnostics13193067
|
|
19954
Okamura K, Inoue H, Tanaka K, Ikematsu Y, Furukawa R, Ota K, Yoneshima Y, Iwama E, Okamoto I.
Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
Cancer Sci
2023
114(3):1095-1107
PubMed ID: 36369966
DOI: 10.1111/cas.15645
|
|
21089
Sakura K, Sasai M, Funaki S, Shintani Y, Okumura M, Kaneda Y.
Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study.
Cancers (Basel)
2023
15(3)
PubMed ID: 36765886
DOI: 10.3390/cancers15030929
|
|
21461
Nakagiri T, Amatya VJ, Kushitani K, Kambara T, Aoe K, Endo I, Miyata Y, Okada M, Takeshima Y.
SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
Am J Surg Pathol
2023
PubMed ID: 37899530
DOI: 10.1097/PAS.0000000000002147
|
|
17590
Hagiyama M, Mimae T, Wada A, Takeuchi F, Yoneshige A, Inoue T, Kotoku N, Hamada H, Sekido Y, Okada M, Ito A.
Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma
Front Cell Dev Biol
2022
10:945007
PubMed ID: 35903548
DOI: 10.3389/fcell.2022.945007
|
|
18220
Tatsumi S, Takeuchi M, Fujii T, Sugimoto A, Sekita-Hatakeyama Y, Nishikawa T, Uchiyama T, Morita K, Itami H, Takeda M, Yamazaki M, Ohbayashi C.
Evaluation of DNA/RNA quality from cell block of malignant mesothelioma and lung adenocarcinoma
Diagn Cytopathol
2022
50(6):273-283
PubMed ID: 35384396
DOI: 10.1002/dc.24960
|
|
20462
Fujii Y, Amatya VJ, Kushitani K, Suzuki R, Kai Y, Kambara T, Takeshima Y.
Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1.
Oncol Rep
2022
47(2)
PubMed ID: 34859258
DOI: 10.3892/or.2021.8238
|
|
20093
Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, Tan ST, Peng RW, Yao F.
NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
Cancers (Basel)
2021
13(7)
PubMed ID: 33805359
DOI: 10.3390/cancers13071561
|
|
20560
Abukar A, Wipplinger M, Hariharan A, Sun S, Ronner M, Sculco M, Okonska A, Kresoja-Rakic J, Rehrauer H, Qi W, Beusechem VWV, Felley-Bosco E.
Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A.
Cells
2021
10(12)
PubMed ID: 34944051
DOI: 10.3390/cells10123543
|
|
16120
Kanayama M, Oyama R, Mori M, Taira A, Shinohara S, Kuwata T, Takenaka M, Yoneda K, Kuroda K, Ohnaga T, Kato Y, Tanaka F.
Novel circulating tumor cell-detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma
Oncol Lett
2021
22(1):522
PubMed ID: 34025789
DOI: 10.3892/ol.2021.12783
|
|
6938
Okonska A, Bühler S, Rao V, Ronner M, Blijlevens M, van der Meulen-Muileman IH, de Menezes RX, Wipplinger M, Oehl K, Smit EF, Weder W, Stahel RA, Penengo L, van Beusechem VW, Felley-Bosco E.
Functional genomic screen in mesothelioma reveals that loss of function of BRCA1-associated-protein-1 induces chemoresistance to ribonucleotide reductase inhibition.
Mol Cancer Ther
2020
19(2):552-563
PubMed ID: 31619462
DOI: 10.1158/1535-7163.MCT-19-0356
|
|
12125
Fujii T, Itami H, Uchiyama T, Morita K, Nakai T, Hatakeyama K, Sugimoto A, Shimada K, Tsuji S, Ohbayashi C.
HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells.
Biochem. Biophys. Res. Commun.
2020
PubMed ID: 32284171
DOI: 10.1016/j.bbrc.2020.03.172
|
|
13129
Kojima M, Kajino K, Momose S, Wali N, Hlaing MT, Han B, Yue L, Abe M, Fujii T, Ikeda K, Hino O.
Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.
Respir Res
2020
PubMed ID: 32677949
DOI: 10.1186/s12931-020-01449-2
|
|
13171
Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid RA, Peng RW.
Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.
Cancers (Basel)
2020
PubMed ID: 32824422
DOI: 10.3390/cancers12082310
|
|
13236
Jotatsu T, Izumi H, Morimoto Y, Yatera K.
Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis.
Oncol Rep
2020
PubMed ID: 33000251
DOI: 10.3892/or.2020.7778
|
|
13275
Sakai K, Nishiuchi T, Tange S, Suzuki Y, Yano S, Terashima M, Suzuki T, Matsumoto K.
Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion.
Sci Rep
2020
PubMed ID: 33028834
DOI: 10.1038/s41598-020-72448-y
|
|
13551
Han B, Lee-Okada HC, Ishimine M, Orita H, Nishikawa K, Takagaki T, Kajino K, Yokomizo T, Hino O, Kobayashi T.
Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells
FEBS Open Bio
2020
10(11):2375-2387
PubMed ID: 32961616
DOI: 10.1002/2211-5463.12985
|
|
13608
Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko MK, Kato Y, Tanaka F.
Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the "Universal" CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
Cells
2020
9(4):888
PubMed ID: 32260559
DOI: 10.3390/cells9040888
|
|
14504
Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, Takeshima Y.
Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin
Oncol Lett
2020
19(6):4161-4168
PubMed ID: 32382354
DOI: 10.3892/ol.2020.11504
|
|
11413
Nakayama K, Seike M, Noro R, Takeuchi S, Matsuda K, Kunugi S, Kubota K, Gemma A.
Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.
Anticancer Res.
2019
PubMed ID: 30711938
DOI: 10.21873/anticanres.13156
|
|
11837
Xu D, Yang H, Yang Z, Berezowska S, Gao Y, Liang SQ, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW.
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.
Cancers (Basel)
2019
PubMed ID: 31597321
DOI: 10.3390/cancers11101502
|
|
12382
Yoneda K, Kuwata T, Chikaishi Y, Mori M, Kanayama M, Takenaka M, Oka S, Hirai A, Imanishi N, Kuroda K, Ichiki Y, Ohnaga T, Tanaka F.
Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma
Cancer Sci
2019
110(2):726-733
PubMed ID: 30499156
DOI: 10.1111/cas.13895
|
|
12383
Hino O, Abe M, Han B, Yan Y.
In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma
Cancer Sci
2019
110(5):1518-1524
PubMed ID: 30888083
DOI: 10.1111/cas.14001
|
|
10679
Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.
Capture of mesothelioma cells with 'universal' CTC-chip.
Oncol Lett
2018
15:2635-2640
PubMed ID: 29434985
DOI: 10.3892/ol.2017.7619
|
|
11150
Ohno Y, Shingyoku S, Miyake S, Tanaka A, Fudesaka S, Shimizu Y, Yoshifuji A, Yamawaki Y, Yoshida S, Tanaka S, Sakura K, Tanaka T.
Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways.
Oncogene
2018
37(49):6357-6367
PubMed ID: 30061637
DOI: 10.1038/s41388-018-0405-y
|
|
11107
Xu D, Liang SQ, Yang H, Luthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW.
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
Br. J. Cancer
2018
119(1):65-75
PubMed ID: 29921948
DOI: 10.1038/s41416-018-0145-3
|
|
11217
Matsuura R, Kaji H, Tomioka A, Sato T, Narimatsu H, Moriwaki Y, Misawa H, Imai K, Tsuji S.
Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1.
Sci Rep
2018
PubMed ID: 30250045
DOI: 10.1038/s41598-018-32534-8
|
|
7034
Tsuji S, Washimi K, Kageyama T, Yamashita M, Yoshihara M, Matsuura R, Yokose T, Kameda Y, Hayashi H, Morohoshi T, Tsuura Y, Yusa T, Sato T, Togayachi A, Narimatsu H, Nagasaki T, Nakamoto K, Moriwaki Y, Misawa H, Hiroshima K, Miyagi Y, Imai K.
HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma.
Sci Rep
2017
7:45768
PubMed ID: 28361969
DOI: 10.1038/srep45768
|
|
10043
Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K.
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Lung Cancer
2017
104:98-105
PubMed ID: 28213009
DOI: 10.1016/j.lungcan.2016.12.017
|
|
10329
Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, Schwaller B, Weder W, Stahel RA, Felley-Bosco E.
Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.
Front Genet
2017
8:70
PubMed ID: 28611824
DOI: 10.3389/fgene.2017.00070
|
|
19266
Shigeeda W, Shibazaki M, Yasuhira S, Masuda T, Tanita T, Kaneko Y, Sato T, Sekido Y, Maesawa C.
Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma
Oncotarget
2017
8(55):93729-93740
PubMed ID: 29212185
DOI: 10.18632/oncotarget.20750
|
|
14252
Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.
Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification
Int J Oncol
2017
50(1):129-140.
PubMed ID: 27922671
DOI: 10.3892/ijo.2016.3786
|
|
14253
Satoh T, Tatsuta T, Sugawara S, Hara A, Hosono M.
Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma
Oncotarget
2017
8(26):42466-42477
PubMed ID: 28476017
DOI: 10.18632/oncotarget.17198
|
|
14627
Chikaishi Y, Yoneda K, Ohnaga T, Tanaka F.
EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'
Oncol Rep
2017
37(1):77-82
PubMed ID: 27840987
DOI: 10.3892/or.2016.5235
|
|
9731
Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O.
Establishment of anti-mesothelioma monoclonal antibodies.
BMC Res Notes
2016
9:324
PubMed ID: 27342200
DOI: 10.1186/s13104-016-2128-x
|
|
5814
Lourdes Cortes-Dericks, Laurene Froment, Gregor Kocher, Author information Article notes Copyright and License infor
Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines
Stem Cell Res Ther
2016
7:25
PubMed ID: 26861734
DOI: 10.1186/s13287-016-0282-7
|
|
10036
Jelena Kresoja-Rakic, Esra Kapaklikaya, Gabriela Ziltener, Damian Dalcher, Raffaella Santoro, Brock C Christensen, Kevin C Johnson, Beat Schwaller, Walter Weder, Rolf A Stahel, Emanuela Felley-Bosco
Identification of Cis- And Trans-Acting Elements Regulating Calretinin Expression in Mesothelioma Cells
Oncotarget
2016
7(16):21272-86
PubMed ID: 26848772
DOI: 10.18632/oncotarget.7114
|
|
12632
Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, Takeshima Y.
Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma
Int J Oncol
2016
48(4):1599-607
PubMed ID: 26820394
DOI: 10.3892/ijo.2016.3358
|
|
12680
Kushitani K, Amatya VJ, Mawas AS, Miyata Y, Okada M, Takeshima Y.
Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
Pathobiology
2016
83(1):33-40
PubMed ID: 26735863
DOI: 10.1159/000442092
|
|
13697
Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G.
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity
BMC Cancer
2014
14:304
PubMed ID: 24884875
DOI: 10.1186/1471-2407-14-304
|
|
8088
Iwahori K, Serada S, Fujimoto M, Nomura S, Osaki T, Lee CM, Mizuguchi H, Takahashi T, Ripley B, Okumura M, Kawase I, Kishimoto T, Naka T.
Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
Int. J. Cancer
2011
129:1005-17
PubMed ID: 20949562
DOI: 10.1002/ijc.25716
|
|
8199
Hasegawa S, Koshikawa-Yano M, Saito S, Morokoshi Y, Furukawa T, Aoki I, Saga T.
Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.
Int. J. Cancer
2011
128:2138-46
PubMed ID: 20617513
DOI: 10.1002/ijc.25547
|
|
19029
Kanamori-Katayama M, Kaiho A, Ishizu Y, Okamura-Oho Y, Hino O, Abe M, Kishimoto T, Sekihara H, Nakamura Y, Suzuki H, Forrest AR, Hayashizaki Y.
LRRN4 and UPK3B are markers of primary mesothelial cells
PLoS One
2011
6(10):e25391
PubMed ID: 21984916
DOI: 10.1371/journal.pone.0025391
|
|
8186
Tsuji S, Tsuura Y, Morohoshi T, Shinohara T, Oshita F, Yamada K, Kameda Y, Ohtsu T, Nakamura Y, Miyagi Y.
Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.
Br. J. Cancer
2010
103:517-23
PubMed ID: 20628387
DOI: 10.1038/sj.bjc.6605786
|
|
8379
Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H, Nakamura T, Matsumoto K.
Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
Int. J. Cancer
2010
127:1948-57
PubMed ID: 20104519
DOI: 10.1002/ijc.25197
|
|
13735
Ito A, Hagiyama M, Mimura T, Matsumoto M, Wakayama T, Iseki S, Yokozaki H, Okada M.
Expression of cell adhesion molecule 1 in malignant pleural mesothelioma as a cause of efficient adhesion and growth on mesothelium
Lab Invest
2008
88(5):504-14
PubMed ID: 18332875
DOI: 10.1038/labinvest.2008.15
|
|
16153
Ishida T, Obata Y, Ohara N, Matsushita H, Sato S, Uenaka A, Saika T, Miyamura T, Chayama K, Nakamura Y, Wada H, Yamashita T, Morishima T, Old LJ, Nakayama E.
Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity
Cancer Immun
2008
8:15.
PubMed ID: 19006261
|
Back
Top
CELL BANK Website
